Lancaster, CANCT06126224Now EnrollingIRB Ready

Psychosis Associated With Alzheimer's Disease Clinical Trial in Lancaster, CA

Access cutting-edge psychosis associated with alzheimer's disease treatment through this clinical trial at a research site in Lancaster. Study-provided care at no cost to qualified participants.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Quick Self-Assessment

See if you qualify for this Lancaster location

Preparing your pre-screening questions…

Expert Care in Lancaster

Access psychosis associated with alzheimer's disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related psychosis associated with alzheimer's disease treatment provided free

Apply for This Lancaster Location

Check if you qualify for this psychosis associated with alzheimer's disease clinical trial in Lancaster, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Lancaster

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Lancaster site if eligible
  4. 4Begin participation

About This Psychosis Associated With Alzheimer's Disease Study in Lancaster

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD. The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Who Can Participate

Inclusion Criteria

Is a male or female aged 55 to 90 years, inclusive, at Screening.
Can understand the nature of the trial and protocol requirements and provide informed consent or assent before any study assessments are performed.
Meets clinical criteria for Possible AD or Probable AD.
Must have a magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain (completed within the past 5 years) taken during or subsequent to the onset of dementia to rule out other central nervous system (CNS) disease that could account for the dementia syndrome, e.g., major stroke, neoplasm, subdural hematoma. If not available, a non-contrast brain MRI or non-contrast head CT must be done during Screening.
Living at the same home or residential assisted-living facility for a minimum of 6 weeks before Screening.
Have an identified study partner who should have daily contact (approximately 10 hours a week or more).
History of psychotic symptoms (meeting International Psychogeriatric Association criteria) (Cummings 2020) for at least 2 months prior to Screening.
CGI-S scale with a score ≥ 4 at Screening and Baseline.
AD subjects are required to have NPI-C: Hallucinations and Delusions (H+D) score of ≥ 6 AND meet at least 1 of the following criteria at Screening and Baseline:
Moderate to severe delusions, defined as NPI-C: Delusions domain score of ≥ 2 on 2 of the 8 items OR
Moderate to severe hallucinations, defined as NPI-C: Hallucinations domain score of ≥ 2 on 2 of the 7 items
MMSE score of 8 to 22, inclusive, at Screening. Key

Exclusion Criteria

Psychotic symptoms that are primarily attributable to a condition other than the AD causing the dementia.
History of major depressive episode with psychotic features during the 12 months prior to Screening.
History of bipolar disorder, schizophrenia, or schizoaffective disorder.
Significant or severe medical conditions including pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, cardiovascular, or oncologic disease or any other condition that, in the opinion of the Investigator, could jeopardize the safety of the subject, ability to complete or comply with the study procedures or validity of the study results.
History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator.
Prior exposure to KarXT.
History of hypersensitivity to KarXT excipients or trospium chloride.
Experienced any significant adverse events (AEs) due to trospium.
Participation in another clinical study in which the subject received an experimental or investigational drug within 3 months before Screening or has participated in more than 2 clinical studies in the 12 months prior to Screening.
Other protocol-defined inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lancaster?

Yes, this clinical trial (NCT06126224) has an active research site in Lancaster, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Psychosis Associated With Alzheimer's Disease Treatment Options in Lancaster, CA

If you're searching for psychosis associated with alzheimer's disease treatment options in Lancaster, CA, this clinical trial (NCT06126224) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lancaster research site is actively enrolling participants for this clinical trial. You'll receive care from experienced psychosis associated with alzheimer's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all psychosis associated with alzheimer's disease clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Lancaster, CA

See all alzheimers disease clinical trials recruiting in Lancaster — not just this study.

Browse Alzheimers Disease Trials in Lancaster →

Browse More Trials by Condition

Alzheimers Disease TrialsSchizophrenia TrialsAnkylosing Spondylitis TrialsErectile Dysfunction TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Lancaster?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Lancaster, CA